Assessment of Serum Pepsinogens with and without Co-Testing with Gastrin-17 in Gastric Cancer Risk Assessment—Results from the GISTAR Pilot Study

Introduction––Serum pepsinogen tests for gastric cancer screening have been debated for decades. We assessed the performance of two pepsinogen assays with or without gastrin-17 for the detection of different precancerous lesions alone or as a composite endpoint in a Latvian cohort. Methods––Within t...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Claudia Robles, Dace Rudzite, Inese Polaka, Olga Sjomina, Lilian Tzivian, Ilze Kikuste, Ivars Tolmanis, Aigars Vanags, Sergejs Isajevs, Inta Liepniece-Karele, Danute Razuka-Ebela, Sergej Parshutin, Raul Murillo, Rolando Herrero, Jin Young Park, Marcis Leja
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2022-07-01
Serie:	Diagnostics
Soggetti:	serum pepsinogens gastrin-17 gastric cancer prevention screening public health
Accesso online:	https://www.mdpi.com/2075-4418/12/7/1746
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!